Patents by Inventor Patrick K. Martin
Patrick K. Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9267130Abstract: Polypeptides having nucleic acid binding activity are provided. Methods of using polypeptides having nucleic acid binding activity are provided. Fusion proteins and methods of using fusion proteins are provided. Fusion proteins comprising a polymerase and a nucleic acid binding polypeptide are provided. Fusion proteins comprising a reverse transcriptase and a nucleic acid binding polypeptide are provided. Methods are provided for amplifying a nucleic acid sequence using a fusion protein comprising a nucleic acid binding polypeptide and a polymerase. Methods are provided for amplifying a nucleic acid sequence using a fusion protein comprising a nucleic acid binding polypeptide and a reverse transcriptase.Type: GrantFiled: September 13, 2012Date of Patent: February 23, 2016Assignee: APPLIED BIOSYSTEMS, LLCInventors: Patrick K. Martin, David A. Simpson, Christine D. Hardy
-
Patent number: 9212352Abstract: Polynucleotides having nucleic acid binding activity are provided. Methods of stabilizing a nucleic acid duplex are provided. Methods of promoting the annealing of complementary nucleic acid strands are provided. Methods of increasing the processivity of a DNA polymerase are provided. Methods of enhancing the activity of a nucleic acid modification enzyme are provided. Fusion proteins are provided. Methods of using fusion proteins are provided. Kits are provided.Type: GrantFiled: September 14, 2012Date of Patent: December 15, 2015Assignee: APPLIED BIOSYSTEMS, LLCInventors: Patrick K. Martin, David A. Simpson
-
Publication number: 20130164817Abstract: Polynucleotides having nucleic acid binding activity are provided. Methods of stabilizing a nucleic acid duplex are provided. Methods of promoting the annealing of complementary nucleic acid strands are provided. Methods of increasing the processivity of a DNA polymerase are provided. Methods of enhancing the activity of a nucleic acid modification enzyme are provided. Fusion proteins are provided. Methods of using fusion proteins are provided. Kits are provided.Type: ApplicationFiled: September 14, 2012Publication date: June 27, 2013Applicant: APPLIED BIOSYSTEMS LLCInventors: Patrick K. MARTIN, David A. Simpson
-
Publication number: 20130089895Abstract: Polypeptides having nucleic acid binding activity are provided. Methods of using polypeptides having nucleic acid binding activity are provided. Fusion proteins and methods of using fusion proteins are provided. Fusion proteins comprising a polymerase and a nucleic acid binding polypeptide are provided. Fusion proteins comprising a reverse transcriptase and a nucleic acid binding polypeptide are provided. Methods are provided for amplifying a nucleic acid sequence using a fusion protein comprising a nucleic acid binding polypeptide and a polymerase. Methods are provided for amplifying a nucleic acid sequence using a fusion protein comprising a nucleic acid binding polypeptide and a reverse transcriptase.Type: ApplicationFiled: September 13, 2012Publication date: April 11, 2013Applicant: APPLIED BIOSYSTEMS, LLCInventors: Patrick K. MARTIN, David A. Simpson, Christine D. Hardy
-
Patent number: 8349600Abstract: Polypeptides having nucleic acid binding activity are provided. Methods of stabilizing a nucleic acid duplex are provided. Methods of promoting the annealing of complementary nucleic acid strands are provided. Methods of increasing the processivity of a DNA polymerase are provided. Methods of enhancing the activity of a nucleic acid modification enzyme are provided. Fusion proteins are provided. Methods of using fusion proteins are provided. Kits are provided.Type: GrantFiled: January 6, 2006Date of Patent: January 8, 2013Assignee: Applied Biosystems, LLCInventors: Patrick K. Martin, David A. Simpson
-
Publication number: 20110086406Abstract: Disclosed herein are chimeric polymerases and methods of making and using same.Type: ApplicationFiled: February 16, 2010Publication date: April 14, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: PATRICK K. MARTIN, David A. Simpson
-
Publication number: 20100159527Abstract: Polypeptides having nucleic acid binding activity are provided. Methods of using polypeptides having nucleic acid binding activity are provided. Fusion proteins and methods of using fusion proteins are provided. Fusion proteins comprising a polymerase and a nucleic acid binding polypeptide are provided. Fusion proteins comprising a reverse transcriptase and a nucleic acid binding polypeptide are provided. Methods are provided for amplifying a nucleic acid sequence using a fusion protein comprising a nucleic acid binding polypeptide and a polymerase. Methods are provided for amplifying a nucleic acid sequence using a fusion protein comprising a nucleic acid binding polypeptide and a reverse transcriptase.Type: ApplicationFiled: August 21, 2009Publication date: June 24, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Patrick K. Martin, David A. Simpson, Christine D. Hardy
-
Publication number: 20080118917Abstract: In some embodiments, the present teachings provide a method for detecting a nucleotide of interest comprising; forming an amplification reaction mixture comprising a mismatched primer, a target polynucleotide, a strand-displacing polymerase lacking 3? to 5? exonuclease activity, a recombinase, and a single-stranded DNA binding protein; hybridizing a mismatched primer to the target polynucleotide to form a primer-target complex; and, detecting the nucleotide of interest by the absence of a primer extension product. In some embodiments, control reactions are performed in which a control polynucleotide is exponentially amplified. Additional methods, as well as reaction mixtures and kits, are also provided.Type: ApplicationFiled: November 21, 2006Publication date: May 22, 2008Applicant: Applera CorporationInventors: Christine D. Hardy, Patrick K. Martin
-
Patent number: 6638718Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: March 17, 2000Date of Patent: October 28, 2003Assignee: Essential Therapeutics, Inc.Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6630303Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: March 17, 2000Date of Patent: October 7, 2003Assignee: Essential Therapeutics, Inc.Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6514746Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial genes which encode the components of a two-component regulatory pair. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: May 20, 1998Date of Patent: February 4, 2003Assignee: Essential Therapeutics, Inc.Inventors: Bret Benton, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6228588Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: March 9, 1999Date of Patent: May 8, 2001Assignee: Microcide Pharmaceuticals, Inc.Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6187541Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: March 9, 1999Date of Patent: February 13, 2001Assignee: Microcide Pharmaceuticals, Inc.Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6037123Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: September 13, 1996Date of Patent: March 14, 2000Assignee: Microcide Pharmaceuticals, Inc.Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun